NCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
Clinical Trials
16 trialsNCT01784861 2021-07-08
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Phase 1/2 Terminated
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01077986 2021-04-21
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT00560963 2020-12-21
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
Novartis
Phase 1/2 Completed
NCT01514110 2019-04-02
Gastric Cancer RAD001 Study
Chinese University of Hong Kong
Phase 1/2 Completed
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01047293 2017-04-04
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase 1/2 Completed
NCT00516165 2017-02-07
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 1/2 Completed
NCT01099527 2015-12-29
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Samsung Medical Center
Phase 1/2 Completed
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated
NCT01009801 2015-07-07
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00522665 2015-05-15
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT01149434 2014-10-06
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
University of Utah
Phase 1/2 Terminated
NCT00390195 2009-07-02
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Unknown